ESI Group at the Farnborough International Airshow 2022
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) , a global simulation and virtual prototyping software partner for the industry, will be present at the Farnborough International Airshow (18 and 22 July 2022). ESI Group will present an outline of aircraft Acoustics for both interior and exterior noise. Besides, The Group will illustrate how virtual reality solutions help power industry 4.0, showcasing and demonstrating its solution for human-centric virtual simulation and collaborative work with IC.IDO.
2 software solutions presented:
- ESI’s flagship Virtual Reality software IC.IDO for human-centric process validation and product integration: facilitating agile design processes, robust manufacturing, and safe maintenance operations.
- ESI’s vibro-acoustics software VA ONE for aircraft interiors and electric aircraft like eVTOL concepts: meeting interior noise level comfort and optimizing exterior noise impact in urban areas
Promising progress in the aircraft industry thanks to digitalization and virtual reality
Digitalization plays a major role in developing sustainable aviation, hydrogen planes, electric aircraft, urban mobility, eVTOLs... Virtual reality helps industries achieve sustainability goals, to secure “first time right”, reduce costs, time and go to market. Throughout the years, Virtual reality upgraded processes, allowing faster turnaround for foundries and composite parts manufacturers, lower scrap rates, manufacturability despite new geometries. Industrials have been able to achieve their desired vibro-acoustic performance and virtually pre-certified products. Besides, the need for physical try-outs and prototypes significantly decreased, paving the way to more efficient assembly steps, increased productivity and output, reduced maintenance costs, and decreased industrial risks for operators.
ESI Group has been operating in the aircraft industry for the last decades. ESI’s aerospace customers leverage the benefits of virtual reality solutions, helping them achieve their goal to producing clean, safe, and productive.
eVTOLS: ESI Group helps foster innovations – interior external noise and comfort
ESI has the mission to help aerospace companies in gearing their digital transformation, to be a partner they can trust to help foster innovations, such as the eVTOLS, that will change the landscape of urban mobility. ESI Group is already helping the pioneers of that segment achieve their product performance and safety targets while meeting stringent noise regulations, reducing noise impact in urban areas and meeting interior aircraft noise comfort levels. ESI Group’s VA One software solution help manufacturers to predict and resolve potential noise and vibration challenges in very early stages of their development process. Thus, meeting safety standards and their objectives for aircraft acoustics, and minimizing weight and controlling costs.
ESI Group’s software solutions for a clean, safe, and productive industry
1. Power systems manufacturer Rolls-Royce uses ESI casting simulation software ProCAST for Product-Process co-design and to collaborate more efficiently with their supply chain towards greater quality parts, avoiding late design changes and eliminating scrap rates in a more sustainable manner.
2. Saab Aerospace Systems relies on ESI composites manufacturing simulation software PAM-COMPOSITES to refine their injection strategies for the next generation aircraft doors, supporting the advanced manufacturing of ever lighter structures.
3. Latécoère counts on the advanced virtual reality capabilities provided by IC.IDO (1), to connect manufacturing engineering teams from around the world on the same virtual platform to secure “First Time Right” production and to train operators remotely, cutting down on travel emissions, yet providing a “learning by doing” approach.
(1) ESI Group at the exhibition: France Pavillion. ESI Group will be part of the GIFAS (& “AsTech”) area in HALL 1 – Booth 13.60 Village ASTech
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high-stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world, and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220717005031/en/
Contact information
ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Verbatee - Press & Shareholder Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 18:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2 It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.3 By depleting cells that produce an abnormal protein called Gd-IgA1 implicated in the pathogenesis, mezagitamab targets early steps in the process lea
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 17:23:00 EET | Press release
Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a trusted growth ecosystem. Our vision is to offer technology-d
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 16:00:00 EET | Press release
Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, President of Experian Software Solutions at Experian. “Experian continues to listen to our clients and focus heavily on product development across
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 15:12:00 EET | Press release
MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of MultiSafepay. In her new role, Lim oversees the overall business strategy and operations of MultiSafepay, leading the company to serve a fast-growing client base of SMEs (small and medium-sized enterprises) in Europe, leveraging innovative solutions to drive their inclusive growth. She now also sits on its board of directors, following approval from the Dutch central bank, De Nederlandsche Bank (DNB). Founder Olaf Geurs, who has served as CEO since establishing MultiSafepay in 1999, will remain Chief Technology Officer (CTO). Geurs will continue to serve on the board of directors, where he and the other existing members will be joined by Lim. In his
Organon Announces Agreement to Divest its JADA ® System for Up to $465 Million to Laborie7.11.2025 14:30:00 EET | Press release
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transfer to Laborie as part of the agreement. “I am incredibly proud of the work the JADA team and Organon have done to help more than 136,000 new mothers in over 20 countries, positioning JADA as a recognized standard of care in postpartum hemorrhage (PPH) management,” said Organon Interim Chief Executive Officer (“CEO”) Joseph Morriss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom